Filtered Listing Testing
BrightFocus-funded research offers new evidence of the importance of tau in the prediction of Alzheimer’s disease which could lead to ways to delay—or even stop—the disease from progressing.
Read about some of the ways BrightFocus Foundation is taking action to reduce health disparities and inequities among underrepresented communities and better meet the precise health needs of these populations.
BrightFocus Foundation celebrates the U.S. Food and Drug Administration’s approval of Syfovre (pegcetacoplan injection), the first-ever treatment to slow the progression of vision loss from geographic atrophy, an advanced form of dry age-related macular degeneration and a leading cause of blindness.
Led by a BrightFocus grantee, a research team has developed a new marker of Alzheimer’s disease neurodegeneration in the blood, paving the way for a more accurate blood test to detect Alzheimer’s disease.
In recognition of Macular Degeneration Awareness Month this February, BrightFocus Foundation, a nonprofit dedicated to ending diseases of mind and sight, is offering a variety of free educational resources to help individuals with macular degeneration and their loved ones navigate the disease.
Studies have shown that taking vitamin and mineral supplements can slow the progression of age-related macular degeneration. Now, a long-term follow-up study offers the strongest findings to date that reaffirm the optimal eye vitamin supplement formula.
Using a molecule found in green tea, an Alzheimer's Disease Research-funded team of biochemists has identified new molecules that can destroy protein tangles in the brain linked to Alzheimer's and related brain diseases.
